The effect of glucagon-like peptide 1 (GLP-1) receptor agonists on cognition: A systematic review of systematic reviews and meta-analyses | Synapse
March 3, 2026Open Access
The effect of glucagon-like peptide 1 (GLP-1) receptor agonists on cognition: A systematic review of systematic reviews and meta-analyses
Key Points
Cognition improves in patients with Alzheimer's disease and type 2 diabetes due to GLP-1 receptor agonists, indicating a possible therapeutic avenue.
Significant improvement was noted across various cognitive domains, although requires larger trials to confirm.
Systematic review and meta-analyses methods confirm positive cognitive impacts supported by multiple studies.
Further research highlights the need for expanded clinical trials to better understand the full impact of GLP-1 on cognition.
Abstract
GLP-1 RAs positively affect cognitive function in AD patients with T2DM. However, their efficacy on disparate cognitive domains requires further replication in larger scale controlled clinical trials.